Cellectar’s CLR 131 receives FDA Orphan Drug Designation for pediatric osteosarcoma
Cellectar Biosciences announces the FDA has granted Orphan Drug Designation to CLR 131, the company’s lead Phospholipid Drug Conjugate™ product candidate, for treatment of pediatric osteosarcoma, a rare pediatric cancer. CLR 131 also received Rare Pediatric Disease Designation for osteosarcoma. September 25, 2018